Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

17
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
17
Hypoglycemia01:26

Hypoglycemia

30
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Influencing factors in knee kinematics following posteriorly stabilized knee arthroplasty: a comprehensive analysis.

Acta orthopaedica Belgica·2025
Same author

Trends For Smaller Medical Journals.

Acta clinica Belgica·2016
Same author

Temperature dependence of the electronic structure of semiconductors and insulators.

The Journal of chemical physics·2015
Same author

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.

British journal of cancer·2015
Same author

[Update on the management of acute viral bronchiolitis: proposed guidelines of Grand Ouest University Hospitals].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013
Same author

[Management of bronchiolitis in general practice and determinants of treatment being discordant with guidelines of the HAS].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013

相关实验视频

Updated: May 3, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

10.4K

血小板糖蛋白IIb/IIIa的合成抑制剂在临床开发中

M Verstraete1

  • 1Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.

Circulation
|February 15, 2000
PubMed
概括
此摘要是机器生成的。

葡萄糖蛋白 (GP) IIb/IIIa受体抑制剂阻断了血小板聚合. 合成抑制剂提供口服活性,但持续时间较短,比abciximab更多的出血,对复原无影响.

更多相关视频

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.1K

相关实验视频

Last Updated: May 3, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

10.4K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.1K

科学领域:

  • 心血管医学 心血管医学
  • 药理学 药理学是指药理学的学科.
  • 血液学 血液学 血液学

背景情况:

  • 血小板聚合是动脉血症的最后一个常见途径,由血小板糖蛋白 (GP) IIb/IIIa受体介导.
  • GP IIb/IIIa受体抑制剂代表了一类药物,其向的是这个最后的共同途径.
  • 现有的阿司匹林和克洛皮多格雷尔等疗法已经在二次预防中发挥了作用.

研究的目的:

  • 审查GP IIb/IIIa受体抑制剂在动脉瘤的二次预防中的作用和比较特征.
  • 为了比较单克隆抗体 (abciximab) 和合成GP IIb/IIIa抑制剂的药理学和临床特征.
  • 评估这些抑制剂在各种动脉栓塞疾病中的有效性和安全性.

主要方法:

  • 对GPIIb/IIIa抑制剂的大规模临床试验和现有文献的审查.
  • 阿布西西马布与性和非性合成GP IIb/IIIa受体抑制剂的比较.
  • 分析有关作用持续时间,口服活性和临床结果 (缺血事件,复原,出血) 的数据.

主要成果:

  • 与合成抑制剂相比,阿布西西马布的作用持续时间较长 (2 周) (活体时数).
  • 合成抑制剂具有潜在的口服活性,并且在与阿司匹林和肝素相结合时,在减少缺血事件方面表现出有效性.
  • 合成抑制剂的短期使用在6个月后没有抑制复原;合成抑制剂的出血风险似乎高于目前使用的剂量中的abciximab.

结论:

  • GP IIb/IIIa抑制剂有效地控制动脉血事件,特别是在接受干预的高风险患者中.
  • 与abciximab相比,合成抑制剂提供了一种潜在的口服替代品,尽管与abciximab相比,它的作用时间较短,出血风险更高.
  • 需要进行进一步的直接比较研究,以充分阐明不同GP IIb/IIIa抑制剂的风险-益处概况.